Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care

Current Opinion in Critical Care

Volumn 16, Issue 6, 2010, Pages 545-549

  Doi, Kent ^a,b   Noiri, Eisei ^a,b   Sugaya, Takeshi ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN INTERNATIONAL COOPERATION AGENCY   (Japan)

Author keywords

acute kidney injury; L type fatty acid binding protein; urinary biomarker

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN; KIDNEY INJURY MOLECULE 1; L TYPE FATTY ACID BINDING PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; POLYMYXIN B IMMOBILIZED FIBER; POLYMYXIN DERIVATIVE; UNCLASSIFIED DRUG;

CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; EPITHELIUM CELL; HEMOPERFUSION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EPITHELIUM; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; TRANSGENIC MOUSE;

ACUTE KIDNEY INJURY; ANIMALS; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; CRITICAL CARE; FATTY ACID-BINDING PROTEINS; HUMANS; INTENSIVE CARE UNITS; MICE; POSTOPERATIVE COMPLICATIONS; SENSITIVITY AND SPECIFICITY; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 78649684702     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32833e2fa4     Document Type: Review

References (37)

1. Chertow GM, Christiansen CL, Cleary PD, et al. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 1995; 155:1505-1511.
2. Chertow GM, Lazarus JM, Paganini EP, et al. Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. J Am Soc Nephrol 1998; 9:692-698.
3. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002; 30:2051-2058.
4. Mehta RL, Pascual MT, Gruta CG, et al. Refining predictive models in critically ill patientswith acute renal failure. J Am Soc Nephrol 2002; 13:1350-1357.
5. Star RA. Treatment of acute renal failure. Kidney Int 1998; 54:1817-1831.
6. Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol 2007; 2:356-365.
7. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int 2008; 73:1008-1016.
8. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7:489-503.
9. Veerkamp JH, Paulussen RJ, Peeters RA, et al. Detection, tissue distribution and (sub)cellular localization of fatty acid-binding protein types. Mol Cell Biochem 1990; 98:11-18.
10. Levi AJ, Gatmaitan Z, Arias IM. Two hepatic cytoplasmic protein fractions, Y and Z, and their possible role in the hepatic uptake of bilirubin, sulfobromophthalein, and other anions. J Clin Invest 1969; 48:2156-2167.
11. Reyes H, Levi AJ, Gatmaitan Z, Arias IM. Studies of Y and Z, two hepatic cytoplasmic organic anion-binding proteins: effect of drugs, chemicals, hormones, and cholestasis. J Clin Invest 1971; 50:2242-2252.
12. Veerkamp JH, Peeters RA, Maatman RG. Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1991; 1081:1-24.
13. Maatman RG, Van Kuppevelt TH, Veerkamp JH. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J 1991; 273 (Pt 3):759-766.
14. Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid binding protein in acute ischemic injury. J Am Soc Nephrol 2007; 18:2894-2902.
15. Pelsers MM. Fatty acid-binding protein as markerfor renal injury. Scand J Clin Lab Invest Suppl 2008; 241:73-77.
16. Sweetser DA, Lowe JB, Gordon JI. The nucleotide sequence of the rat liver fattyacid-binding protein gene. Evidencethatexon 1 encodesan oligopeptide domain shared by a family of proteins which bind hydrophobic ligands. J Biol Chem 1986; 261:5553-5561.
17. Noiri E, Doi K, Negishi K, et al. Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol 2009; 296:F669-679.
18. Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004; 165:1243-1255.
19. Negishi K, Noiri E, Maeda R, et al. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury. Kidney Int 2008; 73:1374-1384.
20. Negishi K, Noiri E, Doi K, et al. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am J Pathol 2009; 174:1154-1159.
21. Doi K, Noiri E, Maeda-Mamiya R, et al. Urinary L-typefattyacid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med (in press).
22. Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008; 73:465-472. (Pubitemid 351186293)
23. Nakamura T, Sugaya T, Node K, et al. Urinary excretion ofliver-typefattyacid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis 2006; 47:439-444.
24. Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S. NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Adv Med Sci 2009; 54:221-224.
25. Ferguson MA,Vaidya V S,Waikar S S, et al. Urinaryliver-typefattyacid- binding protein predicts adverse outcomes in acute kidney injury. Kidney Int 2010; 77:708-714.
26. Nakamura T, Sugaya T, Koide H. Urinary liver-typefattyacid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion. Shock 2009; 31:454-459.
27. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007; 11:R47.
28. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfu-sion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301:2445-2452.
29. Doi K, Noiri E, Negishi K, et al. Role of L-type fatty acid-binding protein in sepsis and sepsis-induced acute kideny injury. J Am Soc Nephrol 2008; 19:635A.
30. Thurman JM, Parikh CR. Peeking into the black box: new biomarkers for acute kidney injury. Kidney Int 2008; 73:379-381.
31. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004; 15:1677-1689.
32. Shapiro NI, Trzeciak S, Hollander JE, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 2009; 37:96-104.
33. Han WK, Wagener G,Zhu Y, et al. Urinary biomarkers in theearlydetection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4:873-882.
34. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73:863-869.
35. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-asso-ciated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res 2008; 31:255-258.
36. Kamijo A, Kimura K, Sugaya T, et al. Urinaryfattyacid-binding protein asa new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004; 143:23-30.
37. Nielsen SE, Sugaya T, Tarnow L, et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009; 32: 1684-1688.